Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA

被引:64
作者
Eggena, M
Cohavy, O
Parseghian, MH
Hamkalo, BA
Clemens, D
Targan, SR
Gordon, LK
Braun, J [1 ]
机构
[1] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[3] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA
[4] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[5] Cedars Sinai Med Ctr, Inflammatory Bowel Dis Res Ctr, Los Angeles, CA 90048 USA
[6] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA
关键词
histone H1; inflammatory bowel disease; monoclonal antibodies; pANCA; ulcerative colitis;
D O I
10.1006/jaut.1999.0340
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Perinuclear anti-neutrophil cytoplasmic antibody (pANCA)(4) is a predominant serum marker of ulcerative colitis (UC), and a familial trait associated with disease susceptibility and disease associated MHC haplotypes. This study characterizes the pANCA antigen defined by representative UC-pANCA human monoclonal antibodies, Fab 5-3 and 5-2. Western blot analysis probed with Fab 5-3 revealed specific binding to a nuclear protein doublet (apparent MW=32-33 kDa) expressed in several cell types. Purification and tryptic peptide sequencing identified the protein as histone H1, and this specificity was confirmed by Fab 5-3 binding to purified H1. Rabbit anti-histone H1 immunostaining and Western blot analysis confirmed that the pANCA epitope is preferentially immunoaccessible in polymorphonuclear neutrophils (PMN). The epitope was localized to the COOH-terminal region by site-specific proteolysis, and recombinant deletants further localized binding activity for both Fab 5-2 and 5-3 to two non-overlapping segments (AA 69-171 and 172-226) associated with a recurring PKKAK motif. Serum IgG binding was detectable to these segments, but was not significantly correlated with pANCA titer or disease status. These findings indicate that histone H1 bears a recurring COOH-terminal epitope recognized by monoclonal ulcerative colitis-associated pANCA marker antibodies, but this epitope is not a predominant specificity of serum pANCA. (C) 2000 Academic Press.
引用
收藏
页码:83 / 97
页数:15
相关论文
共 67 条
  • [51] NEUTROPHIL AUTOANTIBODIES - A GENETIC-MARKER IN PRIMARY SCLEROSING CHOLANGITIS AND ULCERATIVE-COLITIS
    SEIBOLD, F
    SLAMETSCHKA, D
    GREGOR, M
    WEBER, P
    [J]. GASTROENTEROLOGY, 1994, 107 (02) : 532 - 536
  • [52] NEUTROPHIL AUTOANTIBODIES IN ULCERATIVE-COLITIS - FAMILIAL AGGREGATION AND GENETIC-HETEROGENEITY
    SHANAHAN, F
    DUERR, RH
    ROTTER, JI
    YANG, HY
    SUTHERLAND, LR
    MCELREE, C
    LANDERS, CJ
    TARGAN, SR
    [J]. GASTROENTEROLOGY, 1992, 103 (02) : 456 - 461
  • [53] Options for Viagra failures
    Smith, A
    [J]. PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (05): : 188 - 189
  • [54] Sobajima J, 1998, CLIN EXP IMMUNOL, V111, P402
  • [55] Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: Non-histone chromosomal proteins, HMG1 and HMG2
    Sobajima, J
    Ozaki, S
    Osakada, F
    Uesugi, H
    Shirakawa, H
    Yoshida, M
    Nakao, K
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 107 (01) : 135 - 140
  • [56] FOOTPRINTING OF LINKER HISTONES-H5 AND HISTONES-H1 ON THE NUCLEOSOME
    STAYNOV, DZ
    CRANEROBINSON, C
    [J]. EMBO JOURNAL, 1988, 7 (12) : 3685 - 3691
  • [57] MAPPING OF LINEAR EPITOPES OF HUMAN HISTONE H1 RECOGNIZED BY RABBIT ANTI-H1/H5 ANTISERA AND ANTIBODIES FROM AUTOIMMUNE PATIENTS
    STEMMER, C
    BRIAND, JP
    MULLER, S
    [J]. MOLECULAR IMMUNOLOGY, 1994, 31 (14) : 1037 - 1046
  • [58] THIELEMANS K, 1984, J IMMUNOL, V133, P495
  • [59] SEGREGATION OF PANCA ANTIGENIC RECOGNITION BY DNASE TREATMENT OF NEUTROPHILS - ULCERATIVE-COLITIS, TYPE-1 AUTOIMMUNE HEPATITIS, AND PRIMARY SCLEROSING CHOLANGITIS
    VIDRICH, A
    LEE, J
    JAMES, E
    COBB, L
    TARGAN, S
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 1995, 15 (06) : 293 - 299
  • [60] VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707